임상 한눈에 보기

• 1건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• 모집 중 1건 · 완료/종료 0건
• Phase: Phase 1, Phase 2
• Status: Recruiting
• 주요 endpoint: Incidence of adverse events and grade 3 or higher serious adverse events · using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) · Change in the annualized vaso-occlusive pain event (VOE) rates. · Graft rejection defined as having an absolute neutrophil count (ANC) < 500 at 42 days post-infusion · Time to neutrophil recovery defined as the first of 3 measurements on different days when the patient has an absolute neutrophil count (ANC) of ≥500/µL after transplant.
• 등록 대상자(표본 합산): 약 9명

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.